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NUCLEIC ACID APTAMERS AGAINST AGGRECANASES: A NOVEL METHOD FOR 
DEGENERATIVE DISC DISEASE THERAPY 
Yuanyuan Yu and Julian A. Tanner 
Department of Biochemistry, the University of Hong Kong, Hong Kong; Email: yuyy@hku.hk  
Aptamers are short, single-stranded oligonucleotides, which bind to their targets through 3D conformational 
complementarity. Aptamers are frequently called 'chemical antibodies' because of their high specificity and affinity. 
More than 20 aptamers for the treatment of various diseases are evaluated in clinical trials. Role of intervertebral disc is 
to absorb shock and transmit load, allowing the spine to bend and move. Disc degeneration may cause serious low back 
pain and affect daily life. Aggrecanases ADAMTS-4 and -5 are critical proteins involved in the development of 
degenerative disc disease (DDD) and osteoarthritis. They have been used as targets for inhibitor selection against DDD 
in recent studies both in vitro and in silico. Small molecules targeted on catalytic domain of aggrecanases have been 
developed but have broad inhibitory activity which may cause serious side effects. Nucleic acid aptamers can potentially 
solve this problem. Recent studies on aggrecanases have also been restrained by the low expression level and low 
solubility of the catalytic domain. Our studies have developed new ways to express, refold and purify human  
ADAMTS-4 and ADAMTS-5. ADAMTS-4 and ADAMTS-5 catalytic domain incorporating with disintegrin domain 
and thrombospondin motif are expressed and purified from E. coli with high yield for the first time. Specific aptamers 
will then be tailor selected against each aggrecanase through a process called Systematic Evolution of Ligands by 
Exponential enrichment (SELEX). Selected aptamers will then be characterized and evaluated as a foundation for further 
DDD therapeutic development. 
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MULTIPLE NON-CANONICAL AMINO ACID INCORPORATION FOR THE SITE-SPECIFIC 
AND SYNERGISTIC MODIFICATION IN A SINGLE PROTEIN 
Kanagavel Deepankumar, Saravanan Prabhu Nadarajan, Hyungdon Yun 
School of Biotechnology, Yeungnam University, South Korea; E-mail: hyungdon@ynu.ac.kr  
Incorporating non canonical amino acids (NCAAs) into proteins is a powerful in vivo methodology that has been 
increasingly used. Currently, a number of NCAAs was incorporated into protein with the help the methodology such as 
reassignment of sense (residue specific incorporation) and non sense codon (site specific incorporation). Both methods 
balance one another in many ways. However, these two methods have a similar drawback in that they allow only 
incorporation of a single NCAA into the recombinant protein. Our group has developed an easy method to introduce two 
NCAAs containing different chemical moieties by coupling residue-specific and site-specific incorporation methods in a 
single protein. So far, all the techniques have demonstrated the possibility of introducing MNCAAs into a single protein; 
however, no studies have effectively utilized a multifunctional single protein in an effective way to show potential 
applications. Here, we used the MNCAA incorporation technique for self oriented immobilization (site- specific), to 
improve protein functionality, and for protein labeling (residue specific). For the purpose, we selected the surface 
exposed N-terminal residue (Lys15) of the green fluorescent protein (GFP) as a model protein. We introduced an amber 
codon (Lys15TAG) for the site-specific incorporation of L-DOPA using an evolved Methanococcus jannaschii 
tRNA/synthetase pairs and simultaneously (2S, 4S)-4-fluoroproline (4S-FPro) was selected for residue specific 
incorporation. In the next experiment, we prepared the MNCAAs protein with the methionine (Met) surrogate L-
homopropargylglycine (L-HPG) (residue-specific incorporation) along with L-DOPA (site-specific incorporation) in 
GFP (GFPdphpg). The site-specific incorporation of L-DOPA into the protein will allow the protein to be immobilized 
in a controlled manner through Michael addition, the (2S, 4S)-4-fluoroproline (4S-F-Pro) was selected to improve 
